Company Update (NASDAQ:GILD): FDA approves Gilead Sciences’ HIV drug cocktail

[Reuters] – Gilead Sciences Inc said the U.S. Food and Drug Administration had approved its HIV drug cocktail, Genvoya, to treat patients aged 12 and above. Genvoya, a combination tablet approved as a . . . → Read More: Company Update (NASDAQ:GILD): FDA approves Gilead Sciences’ HIV drug cocktail Similar Articles: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences Announces Fourth Quarter 2015 Dividend Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead’s new HIV drug shows lower side-effects over longer term Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead combo drug fights all genotypes of hep C infection: data
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.